Market Closed - Euronext Paris 16:35:24 15/07/2024 BST 5-day change 1st Jan Change
95.25 EUR -0.63% Intraday chart for bioMérieux +3.53% -5.32%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
BioMérieux: a positive week, analysts optimistic CF
Market Update-Europe closes higher on optimism about US rates RE
TP ICAP Midcap Upgrades bioMérieux to Buy from Hold, Lifts PT MT
Market Update-European stock markets rise in absence of Wall Street RE
BioMérieux Announces USDA-FSIS Field Service Laboratories Selects GENE-UP Pathogenic E. coli Assay as Primary Method for Shiga Toxin-Producing E. coli Detection CI
Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board CI
BioMérieux: FDA waiver for new test CF
BioMérieux Gets US FDA Clearance for Antimicrobial Susceptibility Testing System MT
BioMérieux: FDA clearance for Vitek Reveal CF
BioMérieux: head injury test cleared by the FDA CF
BioMérieux: FDA clearance for Vidas TBI test CF
BioMérieux, Pfizer to Collaborate on Antimicrobial Resistance Initiative in Malawi MT
BioMérieux: initiative against antibiotic resistance in Malawi CF
BioMérieux: the rebound gains momentum, an analyst reinforces its case CF
BioMérieux S.A. acquired assets from Ares Genetics GmbH. CI
BioMérieux: share price rises, analyst remains Buy CF
BIOMÉRIEUX : Berenberg raises its target CF
Deutsche Bank Initiates BioMérieux Coverage at Purchase MT
BIOMÉRIEUX : Deutsche Bank initiates buy coverage CF
BioMérieux: on the rise, Deutsche Bank initiates buy coverage CF
Stifel Reaffirms bioMérieux at Buy, Lifts PT MT
BIOMÉRIEUX : Stifel raises target price CF
Invest Securities Lifts BioMérieux PT, Maintains at Buy MT
Oddo BHF Raises bioMérieux PT, Affirms Neutral Recommendation MT
BIOMÉRIEUX : Oddo BHF raises its target price CF
Chart bioMérieux
More charts
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
95.25 EUR
Average target price
113.8 EUR
Spread / Average Target
+19.46%
Consensus
  1. Stock Market
  2. Equities
  3. BIM Stock
  4. News bioMérieux
  5. Stifel Reaffirms bioMérieux at Buy, Lifts PT